C([O:4][CH:5]([CH3:9])[C:6](O)=[O:7])(=O)C.[F:10][C:11]([F:36])([F:35])[C:12]1[CH:17]=[CH:16][C:15]([C:18]2[N:23]=[CH:22][N:21]=[C:20]([O:24][C:25]3[C:30]4[N:31]=[C:32]([NH2:34])[S:33][C:29]=4[CH:28]=[CH:27][CH:26]=3)[CH:19]=2)=[CH:14][CH:13]=1.C(N=P1(N(CC)CC)N(C)CCCN1C)(C)(C)C.CCN(P1(N(CC2C=CC=CC=2)CCCN1C)=NC(C)(C)C)CC.C=CC1C=CC=CC=1.C=CC1C=CC(C=C)=CC=1.C(=O)([O-])[O-].[K+].[K+]>S(Cl)(Cl)=O>[OH:4][CH:5]([CH3:9])[C:6]([NH:34][C:32]1[S:33][C:29]2[CH:28]=[CH:27][CH:26]=[C:25]([O:24][C:20]3[CH:19]=[C:18]([C:15]4[CH:16]=[CH:17][C:12]([C:11]([F:35])([F:10])[F:36])=[CH:13][CH:14]=4)[N:23]=[CH:22][N:21]=3)[C:30]=2[N:31]=1)=[O:7]A mixture of (+/−)-2-acetoxypropionic acid (56 uL, 0.5 mmol, Fluka) in thionyl chloride (1 mL) was heated at reflux for 3 h. After evaporation of the solvent, the residue was dissolved in THF, and treated with 4-[6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yloxy]-benzothiazol-2-ylamine, (Example 65), (97 mg, 0.25 mmol) and 2-tert-butylimino-2-diethylamino-1,3-dimethyl-perhydro-1,3,2-diazaphosphorine, polymer bound (BEMP resin) (0.17 g, 0.38 mmol, Aldrich). The reaction mixture was stirred at 25° C. for 16 h. The insoluble material was filtered off and washed with CH2Cl2. The filtrate was concentrated and then dissolved in MeOH. Potassium carbonate (69 mg, 0.5 mmol) was added and the reaction mixture was stirred at 25° C. for 2 h. The solvent was evaporated in vacuum and to the residue was added CH2Cl2 (30 mL). After stirring for 5 min, the precipitate was collected by filtration and purified by silica gel chromatography (3:1 of EtOAc/hexanes) to give the title compound. MS (ESI, pos. ion) m/z: 461 (M+1).